Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus PT from Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have received a consensus recommendation of “Buy” from the eight research firms that are currently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $41.20.

A number of research firms have recently issued reports on BCAX. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective on the stock. Wedbush reiterated an “outperform” rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a report on Wednesday, February 12th. Finally, HC Wainwright lifted their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, January 27th.

Hedge Funds Weigh In On Bicara Therapeutics

A number of institutional investors have recently added to or reduced their stakes in BCAX. First Turn Management LLC acquired a new position in Bicara Therapeutics during the third quarter worth $14,324,000. The Manufacturers Life Insurance Company acquired a new position in shares of Bicara Therapeutics in the third quarter valued at $582,000. FMR LLC acquired a new position in shares of Bicara Therapeutics in the third quarter valued at $57,913,000. Walleye Capital LLC acquired a new position in shares of Bicara Therapeutics in the third quarter valued at $809,000. Finally, Vestal Point Capital LP acquired a new position in shares of Bicara Therapeutics in the third quarter valued at $10,825,000.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $13.48 on Friday. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09. The firm has a 50 day moving average of $14.98.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.